Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0S0WR
|
|||
| Drug Name |
Luspatercept
|
|||
| Indication | Anaemia [ICD-11: 3A90; ICD-10: D64.8] | Approved | [1] | |
| Beta thalassemia [ICD-11: 3A50.2; ICD-10: D56.1, D56.3] | Phase 3 | [2] | ||
| Myelodysplastic syndrome [ICD-11: 2A37; ICD-9: 238.7] | Phase 3 | [2] | ||
| Company |
Acceleron Pharma Cambridge, MA Celgene Summit, NJ
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.